Review anchor
Lysine-specific histone demethylase 1A
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
Evidence Snapshot
Lysine-specific histone demethylase 1A
CHEMBL6136
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Lysine-specific histone demethylase 1A as ChEMBL target CHEMBL6136, mapped to UniProt O60341. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL6136
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-14
www.ebi.ac.uk
UniProt accession
O60341
Lysine-specific histone demethylase 1A
UniProt accession via ChEMBL component mapping
As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-14
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Lysine-specific histone demethylase 1A matters
Lysine-specific histone demethylase 1A is reviewed as Lysine-specific histone demethylase 1A (UniProt O60341); Lysine-specific histone demethylase 1A shows late clinical disease relevance led by essential thrombocythemia. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 13 approved drugs, 5864 compounds, and 955 assays, with lead potency reaching pChEMBL 10.3.
Protein context
Lysine-specific histone demethylase 1A
Lysine-specific histone demethylase 1A Sequence length is 852 aa.
Review this target as Lysine-specific histone demethylase 1A, mapped to UniProt O60341. Sequence length is 852 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt O60341
Protein
Disease context
essential thrombocythemia
Lysine-specific histone demethylase 1A shows late clinical disease relevance led by essential thrombocythemia. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include BOMEDEMSTAT.
Start review with essential thrombocythemia because it currently carries late clinical support. Linked drugs include BOMEDEMSTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Late clinical
1 linked drug
Activity base
Portfolio and assay base
ChEMBL currently tracks 13 approved drugs, 5864 compounds, and 955 assays for this target. The dominant activity type is IC50. CHEMBL4798849 is the current potency anchor at pChEMBL 10.3.
Use CHEMBL4798849 as the tractability anchor when discussing potency (pChEMBL 10.3).
Activity source · ChEMBL 36 via Core Engine
13 approved
pChEMBL 10.3
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Lysine-specific histone demethylase 1A matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt O60341, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why essential thrombocythemia is currently treated as late clinical support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
5864
Total Compounds
955
Total Assays
13
Approved Drugs
IC50: 9921.0, KI: 518.0, EC50: 62.0, KD: 104.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL4798849
|
10.3 | IC50 | — |
|
|
No preferred name
CHEMBL4762799
|
10.2 | IC50 | — |
|
|
No preferred name
CHEMBL5970037
|
10.2 | IC50 | — |
|
|
No preferred name
CHEMBL6002210
|
10.2 | IC50 | — |
|
|
No preferred name
CHEMBL5767321
|
10.2 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
CAPSAICIN
CHEMBL294199
|
2009 |
|
|
FENOLDOPAM
CHEMBL588
|
1997 |
|
|
AMSACRINE
CHEMBL43
|
1987 |
|
|
TRANYLCYPROMINE
CHEMBL3989843
|
1961 |
Source Header